OncoMatch/Clinical Trials/NCT03819296
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Is NCT03819296 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Infliximab and Vedolizumab for clinical stage 0 cutaneous melanoma ajcc v8.
Treatment: Infliximab · Prednisone · Vedolizumab — This trial studies the role of the gut microbiome and effectiveness of a fecal transplant on medication-induced gastrointestinal (GI) complications in patients with melanoma or genitourinary cancer. The gut microbiome (the bacteria and microorganisms that live in the digestive system) may affect whether or not someone develops colitis (inflammation of the intestines) during cancer treatment with immune-checkpoint inhibitor drugs. Studying samples of stool, blood, and tissue from patients with melanoma or genitourinary cancer may help doctors learn more about the effects of treatment on cells, and help doctors understand how well patients respond to treatment. Treatment with fecal transplantation may help to improve diarrhea and colitis symptoms.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Non-Small Cell Lung Carcinoma
Tumor Agnostic
Disease stage
Required: Stage I, IA, IB, II, IIA, IIB, III, IIIA, IIIB, IIIC, IV, IVA, IVB
Clinical Stage I Cutaneous Melanoma AJCC v8; Clinical Stage IA Cutaneous Melanoma AJCC v8; Clinical Stage IB Cutaneous Melanoma AJCC v8
Prior therapy
Must have received: checkpoint inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify